AAD 2023: Extensive updates from Galderma’s broad and innovative portfolio through posters and presentation sessions
Galderma is the only pure-play dermatology category leader, with more than 40 years of heritage in dermatology. Its continued commitment to delivering science and innovation across a highly differentiated portfolio is reflected in its extensive presence at AAD. More details on Galderma’s scientific poster presentations can be found below.
|
Abstract # and Title |
First Author |
Presentation Date/Time (ET) |
|
Prurigo nodularis |
||
|
Abstract #45996 Nemolizumab monotherapy improves itch, skin lesions and sleep disturbance in patients with prurigo nodularis: Results from a phase 3 trial (OLYMPIA 2) |
Shawn Kwatra |
Late-breaker: Oral March 18, 2023 10:00-10:10 AM Theater B
|
|
Abstract #40893 Risk of myocardial infarction in patients with prurigo nodularis in the UK |
Hannah Cornman |
Oral e-poster |
|
Abstract #44477 Cigarette smoking, alcohol use and obesity among patients with prurigo nodularis in the UK |
Viviane Liao |
Oral e-poster |
|
Abstract #44469 Risk of suicidal ideation and suicide attempt in patients with prurigo nodularis in US |
Anusha Kambala |
e-poster |
|
Abstract #44486 Potentially inappropriate medication use among older adults with prurigo nodularis in US |
Anusha Kambala |
e-poster |
|
Acne |
||
|
Abstract #41942 Improving acne care recommendations from personalizing acne: consensus of experts (PACE) |
Alison M Layton |
Mar 17, 2023 8:50-8:55 AM Level 1, Hall E, Center 1 |
|
Abstract #40148 Phase 3 pooled analysis of safety and efficacy of trifarotene 0.0005% cream with the adolescent population |
Adelaide Hebert |
e-poster |
|
Abstract #42077 Trifarotene in context: exploring the acne burden in Latin America |
Jerry Tan |
e-poster |
|
Abstract #42061 Trifarotene effects on the acne-related gene expression |
Brigitte Dreno |
e-poster |
|
Abstract #41944 Re-formulating the old tretinoin: unique microencapsulated tretinoin with microencapsulated benzoyl peroxide combination for acne vulgaris |
Hilary Baldwin |
e-poster |
|
Abstract #43621 An evaluation of the phototoxic and photoallergic potential of microencapsulated benzoyl peroxide and microencapsulated tretinoin (E-BPO/T, 3%/0.1%) applied topically to the skin of healthy subjects |
Jeffrey Sugarman |
e-poster |
|
Rosacea |
||
|
Abstract #41694 Evolution of benzoyl peroxide: microencapsulated 5% cream to improve tolerability in papulopustular rosacea |
Hilary Baldwin |
Mar 17, 2023 8:45-8:50 AM Level 1, Hall E, Center 1 |
|
Abstract #42280 Ivermectin therapy for rosacea: software platform to quantify changes in erythema and skin texture (IIT) |
Martin Schaller |
Mar 17, 2023 9:50-9:55 AM Level 1, Hall E, Center 1 |
|
Abstract #41921 Efficacy of subantibiotic doxycycline in rosacea: focus on patient reported outcomes |
Hilary Baldwin |
e-poster |
|
Abstract #42739 Micrencapsulated benzoyl peroxide 5% is well accepted by patients with rosacea: patient-reported outcomes and results from two phase 3 randomized vehicle-controlled trials |
Neal D. Bhatia |
e-poster |
|
Abstract #42421 Topical ivermectin in cular and cutaneous rosaea (IIT) |
Martin Schaller |
e-poster |
|
Sensitive skin (consumer) |
||
|
Abstract #42528 Subject Perception of An OTC Healing Ointment to Prevent / Heal Diaper Rash in Infants |
Matthew Meckfessel |
e-poster |
|
Abstract #42533 Comparison of Two OTC Itch Relief Products After Single Application
|
Matthew Meckfessel |
e-poster |
|
Abstract #42510 Utilization of a Daily Oil-Free Facial Moisturizer with SPF 35 in Subjects with Skin of Color
|
DiAnne Davis |
e-poster |
|
Abstract #42538 Efficacy, Tolerability, and Acceptability of a 2.6% Benzoyl Peroxide Acne Cleanser Specifically Designed for Sensitive Skin
|
James Q Del Rosso |
e-poster |
|
Abstract #42656 Heatmap Evaluation of Facial Hydration
|
Matthew Meckfessel |
e-poster |
|
Aesthetics |
||
|
Abstract #42408 Improvements in at-rest glabellar lines after treatment with abobotulinumtoxinA |
Sue Ellen Cox |
Mar 17, 2023 10:30-10:35 AM Level 1, Hall E, Center 1 |
|
Abstract #41680 How Glabellar Line Severity at Baseline Can Affect Efficacy in Neurotoxin Trials |
Joely Kaufman-Janette |
e-poster |
|
Abstract #42188 A Study Evaluating the Safety and Effectiveness of Hyaluronic Acid Filler for Correction of Infraorbital Hollow (IOH, Tear Trough Study) |
Brian Biesman |
e-poster |
|
Abstract #41448 Ten-year Global Post-market Safety Surveillance of Delayed Complications with a Flexible Cheek Filler |
Joel Cohen |
e-poster |
|
Abstract #41464 A Randomized, Controlled Study to Assess Effectiveness and Safety of Correction of Cheek Wrinkles Using a Biostimulatory Poly-L Lactic Acid Injectable Implant |
Sabrina Fabi |
e-poster |
For further information:
|
Christian Marcoux, M.Sc. Chief Communications Officer christian.marcoux@galderma.com +41 76 315 26 50 |
Zach Randles-Friedman Head of U.S. Communications zach.randles-friedman@galderma.com +1 305 299 5700
|
|
Rachel Mooney Global Franchise Communications +41 76 261 64 41 |
|